Updated clinical trial simulation software saves time and money

3 Jun 2019

One customer saves $25m and 3 years' development time in their clinical development strategy.

Data analysis and clinical trial software specialist, Exploristics, plans to launch an updated version of its cloud-based data analytics platform for clinical trial design, KerusCloud 2.0, by the end of the summer.

Updated clinical trial simulation software saves time and money

The groundbreaking software offers unique second-generation simulation capabilities providing a virtual environment for optimising clinical study design and data analysis through the processing power of cloud computing.

First launched in 2018, KerusCloud is currently the only software available that can simulate trials with multiple correlated outcomes, allowing it to untangle the complex relationships between the many biological factors that can influence a study’s outcome. Its cloud-based approach makes the simulation of complex studies an affordable and accessible option regardless of project size.

KerusCloud 2.0 builds on its unique capability enabling more realistic clinical trial simulations thanks to a new feature that generates correlated data for sub-groups within a patient population, facilitating the investigation of precision medicine or adaptive development pathways.

This means that clusters of patients in a clinical trial grouped by factors such as genetics, risk factors and biological sub-types can be looked at in greater detail, enabling clinical development teams to pursue more complex clinical strategies with in-silico design tools.

The latest version also delivers an enhanced user experience with simulations that are 96 times faster allowing users to explore a greater range of options in a much shorter time period. In addition, increased security features have been added, such as multi-factor authentication.

KerusCloud 2.0 also provides improved, interactive graphical representations that allow users to explore multiple design scenarios for their trial to make informed data-driven decisions aligned to their clinical and business objectives.

Dr Aiden Flynn, CEO of Exploristics, who founded the business in 2009, said: “We’ve already witnessed the profound difference KerusCloud can make to our customers’ clinical trials, with one customer saving $25m and 3 years' development time in their clinical development strategy.”

“The updated KerusCloud 2.0 puts clinical development teams at the forefront of complex study design supporting key-decision-making to optimise and accelerate clinical development strategies.”

To support KerusCloud 2.0, Exploristics will be offering enhanced consulting services with a dedicated team of experts available to ensure that customers can reap the full benefit of the new version as they confront the challenges of increasingly complex clinical scenarios.

Dr Flynn continued: “We work continuously to ensure our software can meet the evolving needs of clinical development teams and provide them with the necessary support to implement its unique capabilities for optimising, data-driven clinical trial design.

“Removing barriers to state-of-the-art clinical trial planning is vital to transforming global clinical practice and improving the quality of clinical research and we believe KerusCloud 2.0 will play a key role in that.”

The potential of the KerusCloud platform to transform the speed and efficiency of bringing new medicines to market has been recognised by government bodies and Exploristics was recently awarded a £1m Innovate UK loan to extend its capabilities by integrating it into an intelligent software ecosystem.

The KerusCloud Ecosystem will be revolutionary, enabling access to diverse clinical data sources to create an unparalleled knowledge base for selected therapeutic areas and development programs. Evolving with use, the ecosystem will inform and generate the most accurate study simulations available to date, supporting the complex trial planning now needed in the development of new therapeutic interventions.

Read More

Related news

Funding to accelerate delivery of Univercells' vaccine portfolio

Funding to accelerate delivery of Univercells' vaccine portfolio

11 Oct 2019

European financing to support Univercells’ R&D investments to develop four essential and undersupplied global health vaccines to be produced at affordable prices, high quality and large volumes.

Read more 
Industrial-scale manufacture of therapeutic exosomes

Industrial-scale manufacture of therapeutic exosomes

10 Oct 2019

Coordinated purification process development service accelerates progress to clinical trials, and scale-up manufacturing.

Read more 
BASF and Biomillenia join forces in microbiome research to promote healthy skin

BASF and Biomillenia join forces in microbiome research to promote healthy skin

7 Oct 2019

Research aims to identify novel dermocosmetic active ingredients via unique microbiome-on-a-chip technology.

Read more 
Arctoris secures funding to advance novel robotic drug discovery platform

Arctoris secures funding to advance novel robotic drug discovery platform

1 Oct 2019

Platform will enable scientists and biotechnology entrepreneurs worldwide to make discoveries faster and more efficiently,

Read more 
Data on lead ADC demonstrates effective tumour regression

Data on lead ADC demonstrates effective tumour regression

1 Oct 2019

IKS01 shows marked anti-tumour efficacy in pre-clinical models of ovarian and lung cancer.

Read more 
Researchers develop less toxic anti-cancer drug

Researchers develop less toxic anti-cancer drug

24 Sep 2019

New drug works like a ‘magic bullet’ that is delivered directly to the mitochondria of cancer cells.

Read more 
EC approves its first plant-derived cannabis-based medicine

EC approves its first plant-derived cannabis-based medicine

24 Sep 2019

Epidyolex (cannabidiol) approved for the treatment of seizures in patients with two rare, severe forms of childhood-onset epilepsy.

Read more 
Study demonstrates potential of blood test for early lung cancer detection

Study demonstrates potential of blood test for early lung cancer detection

16 Sep 2019

Ground-breaking trial demonstrates potential of blood test which harnesses the power of the immune system to reduce late detection of lung cancer.

Read more 
M2i Life Sciences completes a historic fundraising of 60 million Euros

M2i Life Sciences completes a historic fundraising of 60 million Euros

16 Sep 2019

To support its strong growth, M2i Life Sciences has concluded a capital increase of 60 million Euros with five leading investors (ADM Capital, Eurazeo Growth, Téthys Invest, Creadev and France 2i fund managed by RAISE Impact).

Read more 
FUJIFILM Irvine Scientific launches BalanCD Gal Supplement for biotherapeutic development

FUJIFILM Irvine Scientific launches BalanCD Gal Supplement for biotherapeutic development

10 Sep 2019

Delivers enhanced galactosylation for improved protein quality, and antibody binding and function.

Read more